NASDAQ · BRTX
BioRestorative Therapies, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BRTX: Nov 11, 2026
BioRestorative Therapies, Inc. Common Stock (NV) is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-2.6. The reported EPS for the same quarter last year was $-7.6.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-2.60 | $-2.60 | $-2.60 | 1 |
| Dec 2026 | $-2.60 | $-2.60 | $-2.60 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · RTTNews- Fintel · Sep 15, 7:48 PM EDTBioRestorative Therapies Consensus Price Target Increased by 1,900% to $163.20The average one-year price target for BioRestorative Therapies (NASDAQCM:BRTX) has been revised to $163.20 / share. This is an increase of 1,900.00% from the prior estimate of $8.16 dated August 25, 2026. These figures represent aggregate analyst targets compiled from independen
- Zacks · Aug 19, 5:45 PM EDTAlvotech (ALVO) Reports Q2 Loss, Beats Revenue EstimatesAlvotech (ALVO) delivered earnings and revenue surprises of -83.33% and +6.72%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 14, 9:20 AM EDTClene Inc. (CLNN) Reports Q2 Loss, Beats Revenue EstimatesClene (CLNN) delivered earnings and revenue surprises of -62.16% and +38.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 8:20 AM EDTTarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue EstimatesTarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -104.76% and +5.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · May 29, 10:39 AM EDTWeekly Buzz: AZN, JNJ Get FDA Nod; LLY To Acquire Curevo; APGE Advances Zumilokibart(RTTNews) – This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple therapeutic areas, including primary biliary cholangitis, fatigue, resectable lung cancer, and modera
- RTTNews · May 27, 8:56 AM EDTKaos Capital Takes 4.9% Stake In BioRestorative Therapies; Stock Surges In Pre-Market(RTTNews) – Shares of BioRestorative Therapies, Inc. (BRTX) are up 56% in pre-market trading after Kaos Capital announced it has acquired a 4.9% stake in the company and is seeking immediate engagement with the board to explore strategic options.
- RTTNews · May 27, 3:13 AM EDTBioRestorative Completes Phase 2 Dosing For BRTX-100 For Lumbar Disc Disease; Shares Climb By 20%(RTTNews) – BioRestorative Therapies Inc. (BRTX), a late-stage clinical regenerative medicine company, on Tuesday announced completion of Phase 2 dosing for BRTX-100 in the treatment of chronic lumbar disc disease (cLDD).
- RTTNews · May 26, 1:54 PM EDTBioRestorative Completes Phase 2 Dosing Of BRTX-100; Spine Program Advances Toward 2027 Data(RTTNews) – BioRestorative Therapies Inc. (BRTX), announced completion of patient dosing in its fully enrolled Phase 2 clinical trial of BRTX-100, its lead stem cell-based therapy for chronic lumbar disc disease.
- Zacks · May 15, 12:00 PM EDTWhat Makes Biorestorative Therapies (BRTX) a New Buy StockBiorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · May 14, 7:40 PM EDTBiorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue EstimatesBiorestorative Therapies (BRTX) delivered earnings and revenue surprises of +36.67% and -53.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 11, 6:05 PM EDTCoherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue EstimatesCoherus Oncology (CHRS) delivered earnings and revenue surprises of -38.89% and -14.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 7, 5:55 PM EDTPTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue EstimatesPTC Therapeutics (PTCT) delivered earnings and revenue surprises of +93.35% and +16.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for BioRestorative Therapies, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.